{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:52:24Z","timestamp":1756572744974},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"DOI":"10.7759\/cureus.70259","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T16:05:03Z","timestamp":1727366703000},"source":"Crossref","is-referenced-by-count":1,"title":["Assessment of the Efficacy and Safety of Acalabrutinib in Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta\u2011Analysis"],"prefix":"10.7759","author":[{"given":"Rashad Q","family":"Othman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Bispo JA","year":"2020","unstructured":"Bispo JA, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med. 2020, 10:a034819. 10.1101\/cshperspect.a034819","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.14553","article-title":"Chronic lymphocytic leukemia: a clinical review","volume":"312","author":"Nabhan C","year":"2014","unstructured":"Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014, 312:2265-76. 10.1001\/jama.2014.14553","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted therapy in chronic lymphocytic leukemia","volume":"25","author":"Kipps TJ","year":"2019","unstructured":"Kipps TJ, Choi MY. Targeted therapy in chronic lymphocytic leukemia. Cancer J. 2019, 25:378-85. 10.1097\/PPO.0000000000000416","journal-title":"Cancer J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0637","article-title":"Acalabrutinib and its use in treatment of chronic lymphocytic leukemia","volume":"15","author":"Khan Y","year":"2019","unstructured":"Khan Y, O'Brien S. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Future Oncol. 2019, 15:579-89. 10.2217\/fon-2018-0637","journal-title":"Future Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour JF","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, et al.. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023, 142:687-99. 10.1182\/blood.2022018818","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2040620721990553","article-title":"The role of acalabrutinib in adults with chronic lymphocytic leukemia","volume":"12","author":"Fakhri B","year":"2021","unstructured":"Fakhri B, Andreadis C. The role of acalabrutinib in adults with chronic lymphocytic leukemia. Ther Adv Hematol. 2021, 12:2040620721990553. 10.1177\/2040620721990553","journal-title":"Ther Adv Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13685","article-title":"EMA review of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia","volume":"26","author":"Delgado J","year":"2021","unstructured":"Delgado J, Josephson F, Camarero J, et al.. EMA review of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia. Oncologist. 2021, 26:242-9. 10.1002\/onco.13685","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S219570","article-title":"Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data","volume":"12","author":"Isaac K","year":"2020","unstructured":"Isaac K, Mato AR. Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data. Cancer Manag Res. 2020, 12:2079-85. 10.2147\/CMAR.S219570","journal-title":"Cancer Manag Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009, 62:e1-34. 10.1016\/j.jclinepi.2009.06.006","journal-title":"J Clin Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek M","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008, 111:5446-56. 10.1182\/blood-2007-06-093906","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181b9c5ec","article-title":"Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development","volume":"15","author":"Lebwohl D","year":"2009","unstructured":"Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009, 15:386-94. 10.1097\/PPO.0b013e3181b9c5ec","journal-title":"Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim K","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003, 73:712-6. 10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"ref16","unstructured":"The jamovi project (Version 2.3) [Computer Software]. (2022). Accessed. September 3, 2024:  https:\/\/www.jamovi.org."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Woyach JA, Furman RR, et al.. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021, 137:3327-38. 10.1182\/blood.2020009617","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al.. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021, 39:3441-52. 10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers KA","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, et al.. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica. 2021, 106:2364-73. 10.3324\/haematol.2020.272500","journal-title":"Haematologica"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman JP","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020, 395:1278-91. 10.1016\/S0140-6736(20)30262-2","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun C","year":"2020","unstructured":"Sun C, Nierman P, Kendall EK, et al.. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020, 136:93-105. 10.1182\/blood.2019003715","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan FT","year":"2019","unstructured":"Awan FT, Schuh A, Brown JR, et al.. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019, 3:1553-62. 10.1182\/bloodadvances.2018030007","journal-title":"Blood Adv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd JC","year":"2016","unstructured":"Byrd JC, Harrington B, O'Brien S, et al.. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016, 374:323-32. 10.1056\/NEJMoa1509981","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110451","article-title":"Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1\/2 ACE-CL-001 study","volume":"132","author":"Byrd JC","year":"2018","unstructured":"Byrd JC, Woyach JA, Furman RR, et al.. Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1\/2 ACE-CL-001 study. Blood. 2018, 132:692. 10.1182\/blood-2018-99-110451","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130062","article-title":"Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real-world patients","volume":"134","author":"Yazdy MS","year":"2019","unstructured":"Yazdy MS, Mato AR, Roeker LE, et al.. Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real-world patients. Blood. 2019, 134:4311. 10.1182\/blood-2019-130062","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297472-assessment-of-the-efficacy-and-safety-of-acalabrutinib-in-chronic-lymphocytic-leukemia-cll-a-systematic-review-and-metaanalysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T16:05:07Z","timestamp":1727366707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297472-assessment-of-the-efficacy-and-safety-of-acalabrutinib-in-chronic-lymphocytic-leukemia-cll-a-systematic-review-and-metaanalysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.70259","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}